Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer


Yoruker E. E. , Holdenrieder S., Gezer U.

CLINICA CHIMICA ACTA, vol.455, pp.26-32, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 455
  • Publication Date: 2016
  • Doi Number: 10.1016/j.cca.2016.01.016
  • Journal Name: CLINICA CHIMICA ACTA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.26-32
  • Keywords: Colorectal cancer, Blood-based biomarkers, Liquid biopsy, Circulating tumor cells, Cell-free DNA, DNA methylation, Point mutations, Histone methylation, CIRCULATING TUMOR-CELLS, EPITHELIAL-MESENCHYMAL TRANSITION, FREE DNA, PERIPHERAL-BLOOD, MICROSATELLITE INSTABILITY, HISTONE METHYLATION, PLASMA MICRORNAS, BREAST-CANCER, MUTANT-DNA, SERUM DNA
  • Istanbul University Affiliated: Yes

Abstract

The global burden of colorectal cancer (CRC)-associated morbidity and mortality is-increasing, in part due to a lack of early detection. Direct structural examination techniques, such as colonoscopy, are invasive and can therefore affect the willingness of patients to participate in screening. Recently, the use of "liquid biopsy" has gained considerable attention as a novel source of biomarkers. Blood-based biomarkers could prove to be practical tools for CRC detection, as the monitoring of biomarkers in biological fluids offers many advantages, including minimal invasiveness and easy accessibility. Biomarkers with high specificity and sensitivity can enable the detection of CRC at an early stage, thereby improving prognosis, prediction of treatment response, and recurrence risk. In this review, we summarize that the biomarkers currently thought to have potential for the early detection and monitoring of CRC, including circulating tumor cells, DNA, RNA and proteins. (C) 2016 Elsevier B.V. All rights reserved.